Taiwan HDAC inhibitors companies and pipeline landscape (November 2026) | Drugnews
At least 1 Taiwanese biotech companies are active in HDAC inhibitors, with 1 assets in development or on the market. The most advanced is Anbogen Therapeutics (7784)’s ABT-301 (Phase 1 / Phase 2; Colorectal Cancer). Data as of 2026-11-01; updated as new information becomes available.
Taiwan pipelines
1 / 1
| Anbogen Therapeutics (7784) | 7784 | ABT-301 | HDAC inhibitor | Phase 1 / Phase 2; recruiting | Colorectal Cancer (Diagnosis); Colorectal Cancer Metastatic; Colorectal Cancer (CRC); Immunotherapy | Not disclosed | No dated update | 2025-11-24 |
No matches. Clear the search to show all rows.
Global reference medicines
- Panobinostat / Farydak · Secura Bio · EU approved (2015): relapsed/refractory multiple myeloma with bortezomib + dexamethasone after at least two prior regimens. US approval withdrawn 2022-03-24. Source
- Belinostat / Beleodaq · Acrotech · US accelerated approval (2014): adults with relapsed or refractory PTCL. Confirmatory benefit requirement remains in cited label. Source
- Vorinostat / Zolinza · Merck · US approved (2006): cutaneous manifestations of progressive, persistent or recurrent CTCL on or after two systemic therapies. Source
Recent events
No public update available.
Related Drugnews analysis
FAQ
Which Taiwanese companies are developing HDAC inhibitors?
Currently, 1 companies are included: Anbogen Therapeutics (7784). Their drugs, stages and indications are in the pipeline table above.
Which Taiwan-listed stocks are linked to HDAC inhibitors?
Taiwan-listed companies directly involved in HDAC inhibitors R&D, manufacturing or licensing include: Anbogen Therapeutics (7784). Compiled from public information; this is not investment advice.
Which Taiwanese HDAC inhibitors program is most advanced?
Anbogen Therapeutics (7784)’s ABT-301 is at Phase 1 / Phase 2 (Colorectal Cancer).
What are the leading HDAC inhibitors drugs globally?
Leading approved or advanced programs include: Panobinostat / Farydak（Secura Bio，EU approved (2015): relapsed/refractory multiple myeloma with bortezomib + dexamethasone after at least two prior regimens. US approval withdrawn 2022-03-24.）；Belinostat / Beleodaq（Acrotech，US accelerated approval (2014): adults with relapsed or refractory PTCL. Confirmatory benefit requirement remains in cited label.）；Vorinostat / Zolinza（Merck，US approved (2006): cutaneous manifestations of progressive, persistent or recurrent CTCL on or after two systemic therapies.）.
How often is this data updated?
Data as of 2026-11-01; updated when companies announce new developments or clinical progress. Every entry includes its original source and date.